148 related articles for article (PubMed ID: 32964396)
1. Clinical Evaluation of Proline, Glutamic acid, and Leucine-Rich Protein 1 Expression in Astrocytomas and Correlations with the Proliferation Marker Ki-67.
Padmavathy KP; Vuttaradhi VK; Venu A; D'Cruze L; Saravanan R; Pitani R; Ganesh K; Pacharla H; Rayala SK; Prathiba D; Venkatraman G
J Mol Neurosci; 2021 Apr; 71(4):724-733. PubMed ID: 32964396
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
3. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas.
Thotakura M; Tirumalasetti N; Krishna R
J Cancer Res Ther; 2014; 10(3):641-5. PubMed ID: 25313753
[TBL] [Abstract][Full Text] [Related]
4. The pattern of proline, glutamic acid, and leucine-rich protein 1 expression in Chinese women with primary breast cancer.
Zhang Y; Wang P; Shi M; Sasano H; Chan MS; Dai J; Guo L; Liu M; Wang X; Ma Y; Wang L
Int J Biol Markers; 2014 Mar; 29(1):e1-7. PubMed ID: 24627205
[TBL] [Abstract][Full Text] [Related]
5. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.
Kefalopoulou Z; Tzelepi V; Zolota V; Grivas PD; Christopoulos C; Kalofonos H; Maraziotis T; Sotiropoulou-Bonikou G
J Neurooncol; 2012 Jan; 106(1):23-31. PubMed ID: 21735116
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.
Wang X; Tsang JYS; Lee MA; Ni YB; Tong JH; Chan SK; Cheung SY; To KF; Tse GM
Cancer Res Treat; 2019 Apr; 51(2):706-717. PubMed ID: 30134648
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
Aust S; Horak P; Pils D; Pils S; Grimm C; Horvat R; Tong D; Schmid B; Speiser P; Reinthaller A; Polterauer S
BMC Cancer; 2013 Mar; 13():115. PubMed ID: 23497172
[TBL] [Abstract][Full Text] [Related]
9. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.
Johannessen AL; Torp SH
Pathol Oncol Res; 2006; 12(3):143-7. PubMed ID: 16998593
[TBL] [Abstract][Full Text] [Related]
12. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades.
Esen H; Erdi F; Kaya B; Feyzioglu B; Keskin F; Demir LS
J Neurooncol; 2015 Feb; 121(3):451-8. PubMed ID: 25391969
[TBL] [Abstract][Full Text] [Related]
13. Mitosin and DNA topoisomerase IIalpha: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival.
Korkolopoulou P; Patsouris E; Konstantinidou AE; Christodoulou P; Thomas-Tsagli E; Kouzelis K; Angelidakis D; Rologis D; Davaris P
Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):207-14. PubMed ID: 11556747
[TBL] [Abstract][Full Text] [Related]
14. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
15. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
16. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
17. Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.
Yue WY; Sai K; Wu QL; Xia YF; Yu SH; Chen ZP
Chin J Cancer; 2012 Mar; 31(3):159-65. PubMed ID: 22313596
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
[TBL] [Abstract][Full Text] [Related]
19. Practical value of Ki-67 and p53 labeling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas.
Tihan T; Davis R; Elowitz E; DiCostanzo D; Moll U
Arch Pathol Lab Med; 2000 Jan; 124(1):108-13. PubMed ID: 10629140
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of histological features in diffuse astrocytomas WHO grade II.
Lind-Landström T; Habberstad AH; Sundstrøm S; Torp SH
Int J Clin Exp Pathol; 2012; 5(2):152-8. PubMed ID: 22400076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
